Atrial Fibrillation and Other Arrhythmias in Hypertensive Heart Disease

  • D. E. Athanasiou
  • M. S. Kallistratos
  • L. E. Poulimenos
  • A. J. Manolis
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)


Several different procedures may be involved in the arrhythmogenesis in hypertensive patients. There is a complex of hemodynamic changes, neuroendocrine factors, atrial and ventricular structural remodeling, and electrophysiological changes that is thought to contribute to the onset of cardiac arrhythmias. In this review, we are going to summarize the current state of knowledge based on the latest literature.


Arterial hypertension Atrial fibrillation Arrhythmias Left ventricular hypertrophy 


  1. 1.
    Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899–911. Scholar
  2. 2.
    Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.PubMedGoogle Scholar
  3. 3.
    Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27:963–75.PubMedGoogle Scholar
  4. 4.
    Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–50. Scholar
  5. 5.
    Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.PubMedGoogle Scholar
  6. 6.
    Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423–34. Scholar
  7. 7.
    Grundvold I, Skretteberg PT, Liestol K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension. 2012;59:198–204.PubMedGoogle Scholar
  8. 8.
    Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–4.PubMedGoogle Scholar
  9. 9.
    Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N.PubMedGoogle Scholar
  10. 10.
    Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44:3103–8.PubMedGoogle Scholar
  11. 11.
    Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.PubMedGoogle Scholar
  13. 13.
    Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746–51. Scholar
  14. 14.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.PubMedGoogle Scholar
  15. 15.
    Penado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114:206–10.PubMedGoogle Scholar
  16. 16.
    Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.PubMedGoogle Scholar
  17. 17.
    Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC, on behalf of the SPAF Investigators. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993;43:32–6.PubMedGoogle Scholar
  18. 18.
    Investigators SPAF. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5:147–57.Google Scholar
  19. 19.
    Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW, on behalf of the SPAF Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III Clinical Trials. Stroke. 1999;30:1223–9.PubMedGoogle Scholar
  20. 20.
    Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049–56.PubMedGoogle Scholar
  21. 21.
    Yiu KH, Tse HF. Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications. J Hum Hypertens. 2008;22:380–8.PubMedGoogle Scholar
  22. 22.
    Wright J, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev. 2008;13(3):367–75. Epub 2007 Nov 7. ReviewPubMedGoogle Scholar
  23. 23.
    Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35(6):1669–77.PubMedGoogle Scholar
  24. 24.
    Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008;10:238–41. Scholar
  25. 25.
    De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension. 1998;32:976–82.PubMedGoogle Scholar
  26. 26.
    Ferron L, Capuano V, Ruchon Y, Deroubaix E, Coulombe A, Renaud JF. Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels. Circ Res. 2003;93:1241–8. Scholar
  27. 27.
    Canpolat U, Oto A, Hazirolan T, Sunman H, Yorgun H, Sahiner L, Kaya EB, Aytemir K. A prospective DE-MRI study evaluating the role of TGF-beta1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: new insights into primary fibrotic atriocardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:251–9.PubMedGoogle Scholar
  28. 28.
    Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial hypertension, atrial fibrillation, and hyperaldosteronism: the triple trouble. Hypertension. 2017;69:545–50. Scholar
  29. 29.
    Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802–10. Scholar
  30. 30.
    Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773–81. Scholar
  31. 31.
    Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265–325. Scholar
  32. 32.
    Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation. 1997;90:1686–95.Google Scholar
  33. 33.
    Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol. 1996;7:833–42.PubMedGoogle Scholar
  34. 34.
    Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res. 1994;28:933–46.PubMedGoogle Scholar
  35. 35.
    Savelieva I, Yap YG, Yi G, Guo XH, Hnatkova K, Camm AJ, et al. Relation of ventricular repolarization to cardiac cycle length in normal subjects, hypertrophic cardiomyopathy, and patients with myocardial infarction. Clin Cardiol. 1999;22:649–54.PubMedGoogle Scholar
  36. 36.
    Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Heart. 1994;71:268–73.Google Scholar
  37. 37.
    Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005;91:250–6.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Fialova M, Dlugosova K, Okruhlicova L, Kristek F, Manoach M, Tribulova N. Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodeling. Physiol Res. 2008;57:7–11.PubMedGoogle Scholar
  39. 39.
    Tribulova N, Okruhlicova L, Novakova S, Pancza D, Bernatova I, Pechanova O, Weismann P, Manoach M, Seki S, Mochizuki S. Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of lowK(þ)-induced lethal arrhythmias in isolated rat heart. Exp Physiol. 2002;87:195–205.PubMedGoogle Scholar
  40. 40.
    Ohtsuka S, Kakihana M, Watanabe H, Enomoto T, Ajisaka R, Sugishita Y. Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension. J Hypertens. 1996;14:1349–55.PubMedGoogle Scholar
  41. 41.
    Burke AP, Farb A, Liang YH, Smialek J, Virmani R. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation. 1996;94:3138–45.PubMedGoogle Scholar
  42. 42.
    Erdogan D, Yildirim I, Ciftci O, Ozer I, Caliskan M, Gullu H, et al. Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation. 2007;115:593–9.PubMedGoogle Scholar
  43. 43.
    Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014;12(1):4–15.PubMedGoogle Scholar
  44. 44.
    Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for postmyocardial infarction risk stratification. Circulation. 1992;85:177–97.Google Scholar
  45. 45.
    Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol. 1996;27:1053–60.PubMedGoogle Scholar
  46. 46.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3–16. Scholar
  47. 47.
    O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21(5):821–48.PubMedGoogle Scholar
  48. 48.
    O’Neal WT, Soliman EZ, Qureshi W, Alonso A, Heckbert SR, Herrington D. Sustained pre-hypertensive blood pressure and incident atrial fibrillation: the multi-ethnic study of atherosclerosis. J Am Soc Hypertens. 2015;9:191–6. Scholar
  49. 49.
    Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119:2146–52. Scholar
  50. 50.
    Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S, Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease studies. J Hypertens. 2012;30(5):1004–14. Scholar
  51. 51.
    Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep. 2001;3:209–15.PubMedGoogle Scholar
  52. 52.
    Lavie P, Silverberg D, Oksenberg A, Hoffstein V. Obstructive sleep apnea and hypertension: from correlative to causative relationship. J Clin Hypertens (Greenwich). 2001;3:296–301.Google Scholar
  53. 53.
    Kales A, Bixler EO, Cadieux RJ, Schneck DW, Shaw LC 3rd, Locke TW, VelaBueno A, Soldatos CR. Sleep apnoea in a hypertensive population. Lancet. 1984;2:1005–8.PubMedGoogle Scholar
  54. 54.
    Thomas MC, Dublin S, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr, Smith NL, Psaty BM, Siscovick DS, Heckbert SR. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21:1111–6. Scholar
  55. 55.
    Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G, CardioSis Investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (cardio-sis): an open-label randomised trial. Lancet. 2009;374:525–33. Scholar
  56. 56.
    Okin PM, Hille DA, Larstorp AC, Wachtell K, Kjeldsen SE, Dahlöf B, Devereux RB. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension. 2015;66(2):368–73. Scholar
  57. 57.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. Major II inhibitor Dabigatran publication presenting the results of the RELY trial.PubMedGoogle Scholar
  58. 58.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. Major Xa inhibitor rivaroxaban publication presenting the results of the ROCKET AF trial.PubMedGoogle Scholar
  59. 59.
    Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.PubMedGoogle Scholar
  60. 60.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. Major Xa inhibitor apixaban publication presenting the results of the ARISTOTLE trial.PubMedGoogle Scholar
  61. 61.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.PubMedGoogle Scholar
  62. 62.
    Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.PubMedGoogle Scholar
  63. 63.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedGoogle Scholar
  64. 64.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.PubMedGoogle Scholar
  65. 65.
    Lip GY, Frison L, Grind M, SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752–9. Scholar
  66. 66.
    Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. J Am Heart Assoc. 2015;4. pii: e002015.
  67. 67.
    Vemulapalli S, Hellkamp AS, Jones WS, Piccini JP, Mahaffey KW, Becker RC, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the ROCKET AF Trial. Am Heart J. 2016;178:74–84. Scholar
  68. 68.
    Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116:1204–9.PubMedGoogle Scholar
  69. 69.
    Dzeshka MS, Lip GY. Stroke and bleeding risk assessment: where are we now? J Atr Fibrillation. 2014;6:49–57.Google Scholar
  70. 70.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100. Scholar
  71. 71.
    Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, Koretsune Y, Sakamoto T, Iwade K, Yamamoto M, Takahashi JC, Minematsu K, Bleeding with Antithrombotic Therapy (BAT) Study Group. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke. 2010;41:1440–4. Scholar
  72. 72.
    Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T, Tomita H, Origasa H, J-RHYTHM Registry Investigators. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM registry. J Am Heart Assoc. 2016;5(9). pii: e004075.
  73. 73.
    Badheka AO, Patel NJ, Grover PM, Shah N, Patel N, Singh V, et al. Optimal blood pressure in patients with atrial fibrillation (from the AFFIRM Trial). Am J Cardiol. 2014;114:727–36. Scholar
  74. 74.
    Chatterjee S, Bavishi C, Sardar P, Agarwal V, Krishnamoorthy P, Grodzicki T, et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol. 2014;114:1049–52. Scholar
  75. 75.
    Novo S, Barbagallo M, Abrignani MG, Nardi E, Maria D, Longo GU, Mistretta B, Strano A. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens. 1997;10:843–51.PubMedGoogle Scholar
  76. 76.
    Ijiri H, Kohno I, Yin D, Iwasaki H, Takusagawa M, Iida T, Osada M, Umetani K, Ishihara T, Sawanobori T, Ishii H, Komori S, Tamura K. Cardiac arrhythmias and left ventricular hypertrophy in dipper and non dipper patients with essential hypertension. Jpn Circ J. 2000;64:499–504.PubMedGoogle Scholar
  77. 77.
    Folkeringa RJ, Hartgers J, Tieleman RG, Gorgels AP, Dassen WR, Crijns HJ. Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy. Heart. 2006;92:545–6.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Larsen BS, Kumarathurai P, Falkenberg J, Nielsen OW, Sajadieh A. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J Am Coll Cardiol. 2015;66:232–41.PubMedGoogle Scholar
  79. 79.
    Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med. 1984;77:18–22.PubMedGoogle Scholar
  80. 80.
    Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60:560–5.PubMedGoogle Scholar
  81. 81.
    McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 1987;317:787–92.PubMedGoogle Scholar
  82. 82.
    Ferrara N, Furgi G, Longobardi G, Nicolino A, Acanfora D, Leosco D, et al. Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension. J Hum Hypertens. 1995;9:581–7.PubMedGoogle Scholar
  83. 83.
    Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol. 1985;5:141B–9B.PubMedGoogle Scholar
  84. 84.
    Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens. 2001;19(10):1883–91.PubMedGoogle Scholar
  85. 85.
    Manolis AJ, Beldekos D, Handansis S, et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens. 1998;11:640–8.PubMedGoogle Scholar
  86. 86.
    Novo S. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. Am J Hypertens. 2001;14:637–43.PubMedGoogle Scholar
  87. 87.
    Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereaux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death. The LIFE Study. Circulation. 2007;116:700–5.PubMedGoogle Scholar
  88. 88.
    Alexopoulos A, Perpinia A, Michelakakis N, Kossyvakis C, Deftereos S, Pyrgakis V. Evaluation of left ventricular hypertrophy in patients requiring permanent pacing. Ther Adv Cardiovasc Dis. 2010;4:295–9.PubMedGoogle Scholar
  89. 89.
    Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC, Investigators R. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. Eur Heart J. 2007;28:741–51.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • D. E. Athanasiou
    • 1
  • M. S. Kallistratos
    • 1
  • L. E. Poulimenos
    • 1
  • A. J. Manolis
    • 1
  1. 1.Cardiology Department“Asklepeion” General HospitalVoulaGreece

Personalised recommendations